Document:

EX-4.1

 EXHIBIT 4.1 
 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY APPLICABLE STATE SECURITIES LAWS, AND, EXCEPT AND
PURSUANT TO THE PROVISIONS OF ARTICLE 4 BELOW, MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION THEREOF UNDER THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS, OR PURSUANT TO RULE 144 OR AN EXEMPTION FROM THE
REGISTRATION REQUIREMENTS OF THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS. 
 WARRANT TO PURCHASE COMMON STOCK

  

			
	Corporation:	 	Biolase, Inc., a Delaware corporation
	Number of Shares:	 	80,000 (subject to Section 1.2)
	Class of Stock:	 	Common
	Warrant Price:	 	$2.83 per share
	Issue Date:	 	May 24, 2012
	Expiration Date:	 	May 24, 2017

 This Warrant to Purchase Common Stock (this “Warrant”) certifies that, for good and
valuable consideration, the receipt of which is hereby acknowledged, Comerica Bank, a Texas banking association, or its assignee (“Holder”), is entitled to purchase the number of fully paid and nonassessable shares of the
class of securities (the “Shares”) of Biolase, Inc. (the “Company”) at the Warrant Price, all as set forth above and as adjusted pursuant to the terms of this Warrant, subject to the provisions and upon the
terms and conditions set forth in this Warrant. 
 ARTICLE 1 

EXERCISE 

1.1 Method of Exercise. 
 1.1.1 Cash Exercise. Holder may exercise this Warrant by a duly executed Notice of Exercise in substantially the form attached as Appendix I to the principal office of the Company (or such other
appropriate location as Holder is so instructed by the Company). Unless Holder is exercising the conversion right set forth in Section 1.1.2, Holder shall also deliver to the Company a check, wire transfer (to an account designated by the
Company) or other form of payment acceptable to the Company for the aggregate Warrant Price for the Shares being purchased. 
 1.1.2 Net Issue Exercise. In lieu of exercising this Warrant as specified in Section 1.1.1, Holder may from time to time elect to exercise this Warrant by receiving Shares equal to the
exchange value of this Warrant (or the portion thereof being canceled) by surrender of this Warrant at the principal office of the Company together with such notice of election, in which event the Company shall issue to the Holder a number of Shares
computed as equaling the exchange value using the following formula: 
 X = Y*(A-B)/A 

where: 
 X = the number of Shares to be issued to the Holder. 
 Y = the
number of Shares purchasable under this Warrant. 

 A = the Fair Market Value (as determined pursuant to Section 1.6 below)
of one Share. 
 B = the exercise price (as adjusted to the date of such calculation). 

1.2 Vesting. This Warrant may only be exercised upon and after, and to the extent that, it has vested. This Warrant shall vest and
become exercisable in accordance with the following schedule: 
  

									
	  
 Vesting
Date
	  	Incremental Vested Shares	 	  	Total Vested Shares	 
	 May 24, 2012
	  	 	20,000	  	  	 	20,000	  
	 August 24, 2012
	  	 	20,000	  	  	 	40,000	  
	 November 24, 2012
	  	 	20,000	  	  	 	60,000	  
	 February 24, 2013
	  	 	20,000	  	  	 	80,000	  

 1.3 Delivery of Certificate and New Warrant. Within 30 days after Holder exercises this Warrant
and the Company receives payment of the aggregate Warrant Price, the Company shall deliver to Holder certificates for the Shares acquired and, if this Warrant has not been fully exercised and has not expired, a new warrant representing the Shares
not so acquired. 
 1.4 Replacement of Warrants. In the case of loss, theft or destruction of this Warrant, upon delivery
of an indemnity agreement reasonably satisfactory in form and amount to the Company or, in the case of mutilation, upon surrender and cancellation of this Warrant, the Company at its expense shall execute and deliver, in lieu of this Warrant, a new
warrant of like tenor. 
 1.5 Acquisition of the Company. 

1.5.1 “Acquisition.” For the purpose of this Warrant, “Acquisition” means (a) any
sale, license, or other disposition of all or substantially all of the assets (including intellectual property) of the Company, or (b) any reorganization, consolidation, merger, sale of the voting securities of the Company or other transaction
or series of related transactions where the holders of the Company’s securities before the transaction or series of related transactions beneficially own less than 50% of the outstanding voting securities of the surviving entity after the
transaction or series of related transactions. 
 1.5.2 Treatment of Warrant in the Event of an
Acquisition. The Company shall give Holder written notice at least 20 days prior to the closing of any proposed Acquisition. The Company will use commercially reasonable efforts to cause (i) the acquirer of the Company, (ii) successor
or surviving entity or (iii) parent entity in an Acquisition (the “Acquirer”) to assume this Warrant as a part of the Acquisition. 
 (a) If the Acquirer assumes this Warrant, then this Warrant shall be exercisable for the same securities, cash, and property as would be payable for the Shares issuable upon exercise of the unexercised
portion of this Warrant as if such Shares were outstanding on the record date for the Acquisition and subsequent closing. The Warrant Price shall be adjusted accordingly, and the Warrant Price and number and class of Shares shall continue to be
subject to adjustment from time to time in accordance with the provisions hereof. 
 (b) If the Acquirer refuses
to assume this Warrant in connection with the Acquisition, the Company shall give Holder an additional written notice at least ten (10) days prior to the closing of the Acquisition of such fact. In such event, notwithstanding any other

  
 Page 2 of 7

 
provision of this Warrant to the contrary, Holder may immediately exercise this Warrant in the manner specified in this Warrant with such exercise effective immediately prior to closing of the
Acquisition. If Holder elects not to exercise this Warrant, then this Warrant will terminate immediately prior to the closing of the Acquisition. Notwithstanding any other provision of this Warrant to the contrary if the Acquirer refuses to assume
this Warrant in connection with such Acquisition, other than in connection with an Excluded Acquisition (as defined below), then effective as of the date that is ten (10) days prior to the closing of such Acquisition, the Holder shall have the
option to elect to put this Warrant to the Company for a per Share amount equal to the difference between the Acquisition consideration payable for one Share and the Warrant Price. As used herein, an “Excluded Acquisition” means, an
Acquisition where the consideration that the holders of the Shares are entitled to receive on account of the Shares consists entirely of cash and/or shares of common stock that are publicly traded on a national exchange and where the shares, if any,
receivable by the Holder of this Warrant were the Holder to exercise this Warrant in full immediately prior to the closing of such Acquisition may be publicly re-sold by the Holder in their entirety within the three (3) months following such
closing pursuant to Rule 144 or an effective registration statement under the Act. 
 1.6 Fair Market Value. If the
Shares are traded regularly in a public market, the fair market value of the Shares shall be the closing price of the Shares (or the closing price of the Company’s stock into which the Shares are convertible) reported for the business day
immediately before Holder delivers its Notice of Exercise to the Company. If the Shares are not regularly traded in a public market, the Board of Directors of the Company shall determine fair market value in its reasonable good faith judgment.

 ARTICLE 2 
 ADJUSTMENTS TO THE SHARES 
 2.1 Stock Dividends, Splits, Etc. If the
Company declares or pays a dividend on its common stock payable in common stock, or other securities, other than duly declared stock dividends consistent with past practice, or subdivides the outstanding common stock into a greater amount of common
stock, then upon exercise of this Warrant, for each Share acquired, Holder shall receive, without cost to Holder, the total number and kind of securities to which Holder would have been entitled had Holder owned the Shares of record as of the date
the dividend or subdivision occurred. 
 2.2 Reclassification, Exchange or Substitution. Upon any reclassification,
exchange, substitution, or other event that results in a change of the number and/or class of the securities issuable upon exercise or conversion of this Warrant, Holder shall be entitled to receive, upon exercise or conversion of this Warrant, the
number and kind of securities and property that Holder would have received for the Shares if this Warrant had been exercised immediately before such reclassification, exchange, substitution, or other event. Such an event shall include any automatic
conversion of the outstanding or issuable securities of the Company of the same class or series as the Shares to common stock pursuant to the terms of the Company’s Certificate of Incorporation upon the closing of a registered public offering
of the Company’s common stock. The Company or its successor shall promptly issue to Holder a new warrant for such new securities or other property. The new warrant shall provide for adjustments which shall be as nearly equivalent as may be
practicable to the adjustments provided for in this Article 2 including, without limitation, adjustments to the Warrant Price, the number of securities or property issuable upon exercise of the new warrant and expiration date. The provisions of this
Section 2.2 shall similarly apply to successive reclassifications, exchanges, substitutions, or other events. 
 2.3
Adjustments for Combinations, Etc. If the outstanding Shares are combined or consolidated, by reclassification, reverse split or otherwise, into a lesser Number of Shares, the Warrant Price shall be proportionately increased. If the
outstanding Shares are split or multiplied, by reclassification or otherwise, into a greater Number of Shares, the Warrant Price shall be proportionately decreased. 

  
 Page 3 of 7

 2.4 Reserved. 
 2.5 No Impairment. The Company shall not, by amendment of its Certificate of Incorporation or through a reorganization, transfer of assets, consolidation, merger, dissolution, issue, or sale of
securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms to be observed or performed under this Warrant by the Company, but shall at all times in good faith assist in carrying out all the
provisions of this Article 2 and in taking all such action as may be necessary or appropriate to protect Holder’s rights under this Article 2 against impairment. 
 2.6 Certificate as to Adjustments. Upon each adjustment of the Warrant Price, the Company at its expense shall promptly compute such adjustment, and furnish Holder with a certificate signed by its
Chief Financial Officer setting forth such adjustment and the facts upon which such adjustment is based. The Company shall, upon written request, furnish Holder a certificate setting forth the Warrant Price in effect upon the date thereof and the
series of adjustments leading to such Warrant Price. 
 2.7 Fractional Shares. No fractional Shares shall be issuable
upon exercise of this Warrant and the Number of Shares to be issued shall be rounded down to the nearest whole Share. If a fractional share interest arises upon any exercise of this Warrant, the Company shall eliminate such fractional share interest
by paying Holder an amount computed by multiplying the fractional interest by the fair market value, as determined by the Company’s Board of Directors, of a full Share. 
 ARTICLE 3 
 REPRESENTATIONS AND COVENANTS OF THE COMPANY 

3.1 Representations and Warranties. The Company hereby represents and warrants to, and agrees with, the Holder as follows:

 3.1.1 The initial Warrant Price referenced on the first page of this Warrant shall equal to 120% of the share
price of the Company’s common stock on the date hereof as quoted on NASDAQ. 
 3.1.2 All Shares which may be
issued upon the exercise of the purchase right represented by this Warrant, and all securities, if any, issuable upon conversion of the Shares, shall, upon issuance, be duly authorized, validly issued, fully paid and nonassessable, and free of any
liens and encumbrances except for restrictions on transfer provided for herein or under applicable federal and state securities laws. 
 3.1.3 The Company’s capitalization table delivered to Holder as of the Issue Date is true and complete as of the Issue Date. 
 3.2 Notice of Certain Events. If the Company proposes at any time (a) to declare any dividend or distribution upon its stock, whether in cash, property, stock, or other securities and whether
or not a regular cash dividend; (b) to offer for subscription pro rata to the holders of any class or series of its stock any additional shares of stock of any class or series or other rights; (c) to effect any reclassification or
recapitalization of stock; or (d) to merge or consolidate with or into any other corporation, or sell, lease, license, or convey all or substantially all of its assets, or to liquidate, dissolve or wind up, then, in connection with each such
event, the Company shall give Holder written notice thereof at the same time 

  
 Page 4 of 7

 
and in the same manner as the Company gives notice thereof to the holders of the Company’s outstanding common stock. Upon request, the Company shall provide Holder with such information
reasonably necessary for Holder to evaluate its rights as a holder of this Warrant or the Shares in the case of matters referred to (a), (b), (c) and (d) herein above. 

3.3 Information Rights. So long as the Holder holds this Warrant and/or any of the Shares, except to the extent that any of the
following has been filed on the SEC’s EDGAR system, the Company shall deliver to the Holder (a) promptly after mailing, copies of all communications, information and/or communiqués to the shareholders of the Company, (b) within
ninety (90) days after the end of each fiscal year of the Company, the annual audited financial statements of the Company certified by independent public accountants of recognized standing and (c) within forty-five (45) days after the
end of each of the first three quarters of each fiscal year, the Company’s quarterly, unaudited financial statements. In addition, and without limiting the generality of the foregoing, so long as the Holder holds this Warrant and/or any of the
Shares, the Company shall afford to the Holder the same access to information concerning the Company and its business and financial condition as would be afforded to a holder of the class of Shares under applicable state law and/or any agreement
with any holder of the class of Shares. 
 3.4 Reserved. 

ARTICLE 4 

MISCELLANEOUS 
 4.1 Term; Exercise Upon Expiration. This Warrant is exercisable in whole or in part, at any time and from time to time on or before the Expiration Date set forth above. The Company agrees that
Holder may terminate this Warrant, upon notice to the Company, at any time in its sole discretion. 
 4.2 Legends. This
Warrant and the Shares (and the securities issuable, directly or indirectly, upon conversion of the Shares, if any) shall be imprinted with a legend in substantially the following form: 

THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
“ACT”), OR ANY APPLICABLE STATE SECURITIES LAWS, AND, EXCEPT AND PURSUANT TO THE PROVISIONS OF ARTICLE 4 BELOW, MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION THEREOF UNDER THE ACT AND ANY APPLICABLE
STATE SECURITIES LAWS, OR PURSUANT TO RULE 144 OR AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS. 
 4.3 Compliance with Securities Laws on Transfer. This Warrant and the Shares issuable upon exercise of this Warrant (and the securities issuable, directly or indirectly, upon conversion of the
Shares, if any) may not be transferred or assigned in whole or in part without compliance with applicable federal and state securities laws by the transferor and the transferee. The Company shall not require Comerica Bank (“Bank”)
or a Bank Affiliate (as defined herein) to provide an opinion of counsel or investment representation letter if the transfer is to Bank’s parent company, Comerica Incorporated (“Comerica”), or any other affiliate of Bank
(“Bank Affiliate”), provided that such transferee is an “accredited investor” as defined in Regulation D promulgated under the Act. 
 4.4 Transfer Procedure. After receipt of the executed Warrant, Bank will transfer all of this Warrant to Comerica Ventures Incorporated, a non-banking subsidiary of Comerica and a Bank Affiliate
(“Ventures”). Subject to the provisions of Section 4.3, Holder may transfer all or part of this Warrant or 

  
 Page 5 of 7

 
the Shares issuable upon exercise of this Warrant (or the securities issuable, directly or indirectly, upon conversion of the Shares, if any) by giving the Company notice of the portion of this
Warrant being transferred setting forth the name, address and taxpayer identification number of the transferee and surrendering this Warrant to the Company for reissuance to the transferee(s) (and Holder, if applicable); provided, however, that
Holder may transfer all or part of this Warrant to its affiliates, including, without limitation, Ventures, at any time without notice or the delivery of any other instrument to the Company, and such affiliate shall then be entitled to all the
rights of Holder under this Warrant and any related agreements, and the Company shall cooperate fully in ensuring that any stock issued upon exercise of this Warrant is issued in the name of the affiliate that exercises this Warrant. The terms and
conditions of this Warrant shall inure to the benefit of, and be binding upon, the Company and the holders hereof and their respective permitted successors and assigns. 
 4.5 Notices. All notices and other communications from the Company to the Holder, or vice versa, shall be deemed delivered and effective when given personally or mailed by first-class registered or
certified mail, postage prepaid, or sent via a nationally recognized overnight courier service, fee prepaid, or on the first business day after transmission by facsimile, at such address or facsimile number as may have been furnished to the Company
or the Holder, as the case may be, in writing by the Company or such Holder from time to time. Effective upon the receipt of executed Warrant and initial transfer described in Article 5.4 above, all notices to the Holder shall be addressed as
follows until the Company receives notice of a change of address in connection with a transfer or otherwise: 

Comerica Ventures Incorporated 
 Attn: Warrant Administrator 
 1717 Main
Street, 5th Floor, MC 6406 

Dallas, Texas 75201 
 Facsimile No. (214) 462-4459 
 All notices to the Company shall be addressed
as follows: 
 Biolase, Inc. 

4 Cromwell 
 Irvine, California 92618 
 4.6 Amendments; Waiver. This Warrant and any
term hereof may be amended, changed, waived, discharged or terminated only by an instrument in writing signed by the party against which enforcement of such amendment, change, waiver, discharge or termination is sought. 

4.7 Attorneys’ Fees. In the event of any dispute between the parties concerning the terms and provisions of this Warrant, the
party prevailing in such dispute shall be entitled to collect from the other party all costs incurred in such dispute, including reasonable attorneys’ fees. 
 4.8 Governing Law. This Warrant shall be governed by and construed in accordance with the laws of the State of Delaware, without giving effect to its principles regarding conflicts of law.

 [end of warrant – signature page follows] 

  
 Page 6 of 7

 This Warrant to Purchase Common Stock is executed and delivered as of the Issue Date set
forth above. 
  

			
	BIOLASE, INC.
		
	By:	 	 /s/ Frederick D. Furry

	Name:	 	Frederick D. Furry
	Title:	 	Chief Financial Officer

  
 Page 7 of 7

 APPENDIX I 
 NOTICE OF EXERCISE 
 1. The undersigned hereby elects to purchase
         shares of the common stock of Biolase, Inc. pursuant to the terms of the attached Warrant, and tenders herewith payment of the purchase price of such shares in full. 

2. Please issue a certificate or certificates representing said shares in the name of the undersigned or in such other name as is
specified below: 
 Comerica Ventures Incorporated 
 Attn: Warrant Administrator 
 1717 Main Street, 5th Floor, MC 6406 

Dallas, Texas 75201 
 Facsimile No. (214) 462-4459 
 3. The undersigned represents it is acquiring
the shares solely for its own account and not as a nominee for any other party and not with a view toward the resale or distribution thereof except in compliance with applicable securities laws. 

 

	
	COMERICA VENTURES INCORPORATED or Assignee
	
	  

(Signature)

	
	  
 (Name and
Title)

	
	  
 (Date)

 Appendix I 
 Page 1EX-4.2

 EXHIBIT 4.2 
 AMENDMENT NO. 1 TO WARRANT TO PURCHASE COMMON STOCK 
 This Amendment
No. 1 to Warrant to Purchase Common Stock (“Amendment”) is made, delivered, and effective as of August 6, 2012, by and between Biolase, Inc., a Delaware corporation (“Company”) and
Comerica Ventures Incorporated, a California corporation (“Comerica Ventures”) in order to amend the Warrant to Purchase Common Stock dated May 24, 2012, issued by Company to Comerica Bank, a Texas banking association
(“Warrant”), which Warrant has been transferred to Comerica Ventures. 
 For valuable consideration, Company
and Comerica Ventures agree as follows: 
 1. The Warrant Price, as set forth on page 1 of the Warrant, is hereby amended to be $2.00 per
share. 
 2. Section 1.5.2(b) of the Warrant is amended entirely to read as follows: 

“(b) If the Acquirer refuses to assume this Warrant in connection with the Acquisition, the Company shall give Holder an additional
written notice at least ten (10) days prior to the closing of the Acquisition of such fact. In such event, notwithstanding any other provision of this Warrant to the contrary, Holder may immediately exercise this Warrant in the manner specified
in this Warrant with such exercise effective immediately prior to closing of the Acquisition. If Holder elects not to exercise this Warrant, then this Warrant will terminate immediately prior to the closing of the Acquisition. Notwithstanding any
other provision of this Warrant to the contrary if the Acquirer refuses to assume this Warrant in connection with such Acquisition, other than in connection with an Excluded Acquisition (as defined below), then effective as of the date that is ten
(10) days prior to the closing of such Acquisition, the Holder shall have the option to elect to exercise this Warrant pursuant to Section 1.1.1 for a number of Shares determined using as the “Fair Market Value” the difference
between the Acquisition consideration payable for one Share and the Warrant Price. As used herein, an “Excluded Acquisition” means, an Acquisition where the consideration that the holders of the Shares are entitled to receive on account of
the Shares consists entirely of cash and/or shares of common stock that are publicly traded on a national exchange and where the shares, if any, receivable by the Holder of this Warrant were the Holder to exercise this Warrant in full immediately
prior to the closing of such Acquisition may be publicly re-sold by the Holder in their entirety within the three (3) months following such closing pursuant to Rule 144 or an effective registration statement under the Act.” 

3. This Amendment is not an agreement to any further or other amendment of the Warrant. This Amendment contains the entire agreement of the parties for
the amendment of the Warrant, superseding all negotiations, prior discussions, and preliminary agreements made prior to the date hereof. In executing this Agreement, neither party is relying on any promise or commitment of the other party that is
not in writing signed by the other party. The parties agree that except as expressly amended in this Amendment, the Warrant, as amended, remains in full force and effect and is ratified and confirmed. 

4. Each party represents and warrants to the other that when executed, this Amendment will be a duly authorized, legal, valid, and binding obligation of
such party enforceable in accordance with its terms. 
 5. This Agreement may be executed in one or more counterparts, and by separate parties
on separate counterparts, all of which shall constitute one and the same agreement. 
 [end of amendment—signature page
follows] 

 This Amendment No. 1 to Warrant to Purchase Common Stock is executed and delivered as
of the date first written above. 
  

									
	Biolase, Inc.	 		 	Comerica Ventures Incorporated
					
	By:	 	 Frederick D. Furry
	 		 	By:	 	 LaReeda V. Rentie

	Name:	 	Frederick D. Furry	 		 	Name:	 	LaReeda V. Rentie
	Title:	 	Chief Financial Officer	 		 	Title:	 	Assistant Vice President

  
 - 2 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00207-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00207-of-00352.parquet"}]]